Rheumatic valvular heart disease treated with traditional Chinese medicine: A case report.
Case report
Chinese formulas
Mitral stenosis
Rheumatic heart disease
Traditional Chinese medicine treatment
Valvular damage
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
06 Mar 2023
06 Mar 2023
Historique:
received:
04
11
2022
revised:
19
01
2023
accepted:
13
02
2023
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
18
3
2023
Statut:
ppublish
Résumé
Rheumatic heart disease (RHD) is an autoimmune disease that leads to irreversible valve damage and heart failure. Surgery is an effective treatment; however, it is invasive and carries risks, restricting its broad application. Therefore, it is essential to find alternative nonsurgical treatments for RHD. A 57-year-old woman was assessed with cardiac color Doppler ultrasound, left heart function tests, and tissue Doppler imaging evaluation at Zhongshan Hospital of Fudan University. The results showed mild mitral valve stenosis with mild to moderate mitral and aortic regurgitation, confirming a diagnosis of rheumatic valve disease. After her symptoms became severe, with frequent ventricular tachycardia and supraventricular tachycardia > 200 beats per minute, her physicians recommended surgery. During a 10-day preoperative waiting period, the patient asked to be treated with traditional Chinese medicine. After 1 week of this treatment, her symptoms improved significantly, including resolution of the ventricular tachycardia, and the surgery was postponed pending further follow-up. At 3 -month follow-up, color Doppler ultrasound showed mild mitral valve stenosis with mild mitral and aortic regurgitation. Therefore, it was determined that no surgical treatment was required. Traditional Chinese medicine treatment effectively relieves symptoms of RHD, particularly mitral valve stenosis and mitral and aortic regurgitation.
Sections du résumé
BACKGROUND
BACKGROUND
Rheumatic heart disease (RHD) is an autoimmune disease that leads to irreversible valve damage and heart failure. Surgery is an effective treatment; however, it is invasive and carries risks, restricting its broad application. Therefore, it is essential to find alternative nonsurgical treatments for RHD.
CASE SUMMARY
METHODS
A 57-year-old woman was assessed with cardiac color Doppler ultrasound, left heart function tests, and tissue Doppler imaging evaluation at Zhongshan Hospital of Fudan University. The results showed mild mitral valve stenosis with mild to moderate mitral and aortic regurgitation, confirming a diagnosis of rheumatic valve disease. After her symptoms became severe, with frequent ventricular tachycardia and supraventricular tachycardia > 200 beats per minute, her physicians recommended surgery. During a 10-day preoperative waiting period, the patient asked to be treated with traditional Chinese medicine. After 1 week of this treatment, her symptoms improved significantly, including resolution of the ventricular tachycardia, and the surgery was postponed pending further follow-up. At 3 -month follow-up, color Doppler ultrasound showed mild mitral valve stenosis with mild mitral and aortic regurgitation. Therefore, it was determined that no surgical treatment was required.
CONCLUSION
CONCLUSIONS
Traditional Chinese medicine treatment effectively relieves symptoms of RHD, particularly mitral valve stenosis and mitral and aortic regurgitation.
Identifiants
pubmed: 36926399
doi: 10.12998/wjcc.v11.i7.1600
pmc: PMC10011998
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1600-1606Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
Références
J Transl Med. 2020 Sep 29;18(1):372
pubmed: 32993688
Chin J Integr Med. 2012 Mar;18(3):235-40
pubmed: 22466951
J Cell Mol Med. 2019 Jan;23(1):4-20
pubmed: 30444050
Pharmacol Ther. 2020 Mar;207:107452
pubmed: 31836457
Zhongguo Zhong Yao Za Zhi. 2022 Jan;47(1):244-252
pubmed: 35178936
Lancet. 2016 Mar 26;387(10025):1335-46
pubmed: 27025439
Molecules. 2021 Jul 16;26(14):
pubmed: 34299584
Interv Cardiol Clin. 2018 Jul;7(3):405-413
pubmed: 29983151
Pharmazie. 2020 Mar 20;75(2):42-55
pubmed: 32213234
Platelets. 2017 Mar;28(2):194-202
pubmed: 27560602
J Am Coll Cardiol. 2013 May 14;61(19):2022-3
pubmed: 23501385
Proc Nutr Soc. 2010 Aug;69(3):273-8
pubmed: 20569521
Lancet. 2005 Jul 9-15;366(9480):155-68
pubmed: 16005340
Nat Rev Cardiol. 2020 Mar;17(3):145-154
pubmed: 31519994
Asian Cardiovasc Thorac Ann. 2020 Sep;28(7):371-373
pubmed: 31619045
Biomed Pharmacother. 2019 Apr;112:108599
pubmed: 30798134
FP Essent. 2017 Jun;457:11-16
pubmed: 28671804
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
Mol Med Rep. 2021 Jan;23(1):
pubmed: 33179113
Drug Deliv. 2019 Dec;26(1):860-869
pubmed: 31524010
Inflammation. 2016 Apr;39(2):727-34
pubmed: 26707503
J Atr Fibrillation. 2019 Feb 28;11(5):2124
pubmed: 31139300
Cytokine. 2021 Feb;138:155370
pubmed: 33341346
Asian Cardiovasc Thorac Ann. 2010 Jun;18(3):299-310
pubmed: 20519304